Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...
Principal Financial Group Inc. lifted its stake in shares of Biogen by 3.2% during the third quarter. Principal Financial ...
We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...
On Friday, Biogen Inc (BIIB) stock saw a decline, ending the day at $159.99 which represents a decrease of $-4.90 or -2.97% from the prior close of $164.89. The stock opened at $165.46 and touched a ...
Venturi Wealth Management LLC raised its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 73.8% in the 3rd quarter, ...
(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) Monday announced that the European Commission (EC) has approved Opuviz, a biosimilar to Regeneron Pharmaceuticals' Aflibercept.
On Thursday, Biogen Inc (BIIB) stock saw a decline, ending the day at $164.89 which represents a decrease of $-0.90 or -0.54% from the prior close of $165.79. The stock opened at $165 and touched a ...
OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback